Arcturus Common Stock Total Equity from 2010 to 2024
| ARCT Stock | USD 16.91 0.16 0.94% |
Common Stock Total Equity | First Reported 2012-12-31 | Previous Quarter 26 K | Current Value 27 K | Quarterly Volatility 63.2 K |
Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Interest Expense of 530 K or Selling General Administrative of 55.5 M, as well as many indicators such as Price To Sales Ratio of 5.06, Dividend Yield of 0.0 or PTB Ratio of 3.17. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
Arcturus | Common Stock Total Equity |
Latest Arcturus Therapeutics' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Arcturus Therapeutics Holdings over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Arcturus Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcturus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Arcturus Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 54,354 | |
| Geometric Mean | 28,113 | |
| Coefficient Of Variation | 124.80 | |
| Mean Deviation | 47,545 | |
| Median | 28,405 | |
| Standard Deviation | 67,834 | |
| Sample Variance | 4.6B | |
| Range | 210K | |
| R-Value | 0.09 | |
| Mean Square Error | 4.9B | |
| R-Squared | 0.01 | |
| Significance | 0.76 | |
| Slope | 1,312 | |
| Total Sum of Squares | 64.4B |
Arcturus Common Stock Total Equity History
About Arcturus Therapeutics Financial Statements
Arcturus Therapeutics shareholders use historical fundamental indicators, such as Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcturus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcturus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 29.9 K | 28.4 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.